This drives provider confidence and accelerates adoption
GLP-1s are no longer just weight-loss drugs
Patients with chronic kidney disease, cardiovascular diseases, and those with obesity related complications such as moderate to severe obstructive sleep apnea (OSA) should not use microdoses of GLP-1 medications
Glucagon-like peptide 1 receptor agonists are not associated with an increased risk of ileus or intestinal obstruction in patients with inflammatory bowel disease: a danish nationwide cohort study
Despite GLP-1s being available for years, there are still so many people holding back from treatment due to stigma, lack of access, or concern over how the medication will fit into their lifestyle, said Laura Steele, group VP of U.S
Experienced lawyers can help victims compile necessary documentation to support their claims